The abstract is read at the publisher; the summary is JClub's.
Seven genomic risk loci for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) replicated across UK Biobank and All of Us cohorts, though none reached significance in all three.
- Why it matters: ME/CFS has no diagnostic biomarker, effective treatment, or well-defined causes, and it is female-biased, motivating larger biobank-based genetic discovery and validation.
- What they did: A TarGene genome-wide association study in UK Biobank analyzed 1,268 ME/CFS cases and non-cases defined by electronic health records and survey responses, finding 176 significant variants (FDR < 5%); replication used two disjoint cohorts with 319 and 371 cases.
- The result: Fine-mapping at one replicated locus produced a credible set colocalising with reduced CLYBL expression in putamen, but the CLYBL Arg259 stop-gain variant was not linked to ME/CFS risk; other replicated loci involved BICD1, GRIN2A, CSMD1, and RORA.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.